Opinion|Videos|November 17, 2026

Remaining HIV Care Gaps: Access, Stigma, Insurance, and Funding

Starting therapy has become straightforward, but retention in care still falters under the weight of insurance barriers, social instability, persistent stigma, and uncertain program funding.

This episode, "Remaining HIV Care Gaps: Access, Stigma, Insurance, and Funding," features the panel examining where HIV care still falls short.

Dr. Nguyen identifies accessibility and retention in care as the largest gaps. Initiating therapy after a new diagnosis is relatively straightforward. Keeping people engaged and properly managed over time is far less consistent. Food insecurity, insurance instability, unstable housing, and transportation all undermine access, and Dr. Madison agrees these barriers are substantial. Dr. Nguyen notes that her team spends much of its time securing coverage. Some products must be billed through the medical benefit or a buy-and-bill model, and some are not covered at all.

She also points to persistent stigma, although it has improved considerably. Continued education of families, friends, and communities is needed to reinforce that HIV is a chronic, treatable condition rather than a death sentence. She also suggests that research into self-administered injections could create more options and make adherence easier.

Dr. Burkhart adds a gap specific to injectables: coordinating delivery with provider offices. Messages left with an office often go unanswered. Pharmacists outside the clinic may not know when a patient actually received an injection. His team has seen more success by exchanging cell phone numbers with providers and maintaining constant communication about appointments. Dr. Madison notes that this coordination also prevents wasted product.

Dr. Astle raises funding as a critical gap. In Florida, programs face constant funding battles, and even recent wins have secured only temporary support. He argues that adequate federal funding is crucial and extends well beyond medications. It must cover labs, visits, housing, and food. The epidemic stage may have passed, but new infections continue and many patients remain disengaged from care. Supporting providers financially is essential to closing those gaps. Dr. Madison thanks him for raising this often-overlooked issue.

The next episode in this series, "Beyond One Best HIV Regimen: Shared Decisions and Bictegravir/Lenacapavir," opens the final topic with how pharmacists navigate an expanding menu of options.

Funding supported by Gilead. Content independently developed by Pharmacy Times.


Related to this article